Clinical Trial Update: Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial testing the combination of ZEN003694 and Binimetinib in patients with advanced, metastatic, or unresectable solid tumors with RAS alterations and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ras-mutant Solid Tumors
• Triple-negative Breast Cancer

Drugs mentioned

• Binimetinib (binimetinib)
• ZEN003694

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Status: SUSPENDED